1009 related articles for article (PubMed ID: 17979674)
1. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
Yamagishi S
Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
[TBL] [Abstract][Full Text] [Related]
3. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker.
Yamagishi S; Matsui T
Front Biosci (Elite Ed); 2010 Jun; 2(4):1184-95. PubMed ID: 20515790
[TBL] [Abstract][Full Text] [Related]
4. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
5. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products (AGEs) and their involvement in liver disease.
Hyogo H; Yamagishi S
Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847
[TBL] [Abstract][Full Text] [Related]
7. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
10. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
11. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
12. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
14. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation.
Lanati N; Emanuele E; Brondino N; Geroldi D
Curr Vasc Pharmacol; 2010 Jan; 8(1):86-92. PubMed ID: 19485931
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products and insulin resistance.
Unoki H; Yamagishi S
Curr Pharm Des; 2008; 14(10):987-9. PubMed ID: 18473850
[TBL] [Abstract][Full Text] [Related]
16. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
[TBL] [Abstract][Full Text] [Related]
17. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs).
Yamagishi S; Matsui T
Curr Drug Targets; 2010 Jul; 11(7):875-81. PubMed ID: 20412043
[TBL] [Abstract][Full Text] [Related]
18. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.
Yamagishi S
Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404
[TBL] [Abstract][Full Text] [Related]
19. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
